Login / Signup

Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol.

Eleonora RiccioMario ZanfardinoMonica FranzeseIvana CapuanoPasquale BuonannoLucia FerreriMaria AmiconeAntonio Pisani
Published in: Molecular genetics & genomic medicine (2021)
Our infusion rate escalation protocol is safe and could improve patient compliance, satisfaction and quality of life.
Keyphrases
  • low dose
  • randomized controlled trial
  • open label
  • case report
  • replacement therapy
  • clinical trial
  • heart failure
  • left ventricular
  • smoking cessation